FDA investigating fingolimod after report of rare brain infection
In a Drug Safety Communication, FDA has reported that a patient in Europe being treated for multiple sclerosis and who had no history of using natalizumab (Tysabri) developed progressive multifocal...
View ArticleMS medication may be associated with macula edema
Gilenya (Fingolimod, Novartis), a sphingosine-1-phosphate receptor modulator, became the first FDA-approved oral agent for the treatment of relapsing forms of multiple sclerosis (MS) in September...
View ArticleFDA warning: Case of rare brain infection PML with MS drug Tecfidera
FDA is warning that a patient with multiple sclerosis (MS) who was being treated with Tecfidera (dimethyl fumarate), developed progressive multifocal leukoencephalopathy (PML), a rare and serious...
View ArticleClik here to view.
Oral pain meds overtake injectable therapies as preferred treatment for...
Oral therapies are revolutionizing the treatment paradigm of multiple sclerosis (MS), offering enhanced dosing and patient compliance, according to new analysis. Frost & Sullivan’s A Product and...
View ArticleMS drug linked to rare brain infection
FDA is warning that a case of definite progressive multifocal leukoencephalopathy (PML) and a case of probable PML have been reported in patients taking Gilenya (fingolimod) for multiple sclerosis...
View ArticleMS drugs make major advancements
There is new hope for patients with multiple sclerosis (MS) after positive data on Gilenya and the investigational drug ocrelizumab was presented at the Congress of the European Committee for...
View Article
